IL108750A - Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents - Google Patents

Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents

Info

Publication number
IL108750A
IL108750A IL10875094A IL10875094A IL108750A IL 108750 A IL108750 A IL 108750A IL 10875094 A IL10875094 A IL 10875094A IL 10875094 A IL10875094 A IL 10875094A IL 108750 A IL108750 A IL 108750A
Authority
IL
Israel
Prior art keywords
ludanyl
dialiphatic
xanthines
phenylalkyl
pharmaceutical
Prior art date
Application number
IL10875094A
Other languages
English (en)
Other versions
IL108750A0 (en
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of IL108750A0 publication Critical patent/IL108750A0/xx
Publication of IL108750A publication Critical patent/IL108750A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10875094A 1993-02-26 1994-02-23 Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents IL108750A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26

Publications (2)

Publication Number Publication Date
IL108750A0 IL108750A0 (en) 1994-05-30
IL108750A true IL108750A (en) 2000-09-28

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10875094A IL108750A (en) 1993-02-26 1994-02-23 Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents

Country Status (19)

Country Link
US (1) US5840729A (mo)
EP (1) EP0686155B1 (mo)
JP (1) JPH08512281A (mo)
KR (1) KR100315898B1 (mo)
CN (1) CN1041418C (mo)
AT (1) ATE169019T1 (mo)
AU (1) AU680241B2 (mo)
CA (1) CA2155130C (mo)
DE (1) DE69412073T2 (mo)
DK (1) DK0686155T3 (mo)
ES (1) ES2120025T3 (mo)
HU (1) HUT72677A (mo)
IL (1) IL108750A (mo)
MX (1) MX9401406A (mo)
NO (1) NO311920B1 (mo)
NZ (1) NZ262984A (mo)
TW (1) TW261532B (mo)
WO (1) WO1994019349A1 (mo)
ZA (1) ZA941176B (mo)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
BR0215202A (pt) 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
AU2003239472A1 (en) * 2002-05-15 2003-12-02 Genzyme Corporation Synthesis of benzonitriles and benzimidates
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
JPWO2005056016A1 (ja) * 2003-12-09 2007-07-05 協和醗酵工業株式会社 高次脳機能障害の予防および/または治療剤
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
ZA941176B (en) 1994-09-20
US5840729A (en) 1998-11-24
HU9502495D0 (en) 1995-10-30
DK0686155T3 (da) 1999-02-01
ES2120025T3 (es) 1998-10-16
DE69412073D1 (de) 1998-09-03
MX9401406A (es) 1994-08-31
HUT72677A (en) 1996-05-28
NO311920B1 (no) 2002-02-18
CN1118599A (zh) 1996-03-13
DE69412073T2 (de) 1999-02-18
CN1041418C (zh) 1998-12-30
JPH08512281A (ja) 1996-12-24
ATE169019T1 (de) 1998-08-15
NZ262984A (en) 1997-05-26
NO953353L (no) 1995-08-25
IL108750A0 (en) 1994-05-30
CA2155130A1 (en) 1994-09-01
EP0686155A1 (en) 1995-12-13
KR100315898B1 (ko) 2002-02-28
AU6296894A (en) 1994-09-14
WO1994019349A1 (en) 1994-09-01
CA2155130C (en) 1994-09-01
AU680241B2 (en) 1997-07-24
EP0686155B1 (en) 1998-07-29
NO953353D0 (no) 1995-08-25
TW261532B (mo) 1995-11-01

Similar Documents

Publication Publication Date Title
IL117848A0 (en) Novel compounds a process for their production and pharmacetical compositions containing same
IL108520A0 (en) Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
IL132153A0 (en) Novel compounds
NO952229L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
HU9502065D0 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes
ATE179330T1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
GB9416442D0 (en) Therapeutic heterocycles
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
HU9502495D0 (en) Xanthine derivatives as adenosine a1 receptor antagonists
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
IL112999A0 (en) Crystalline salts of 2,3,4,5- tetrahydro -1h-3-benzazepine compounds, their preparation and pharmaceutical compositions containing them
ES2006619A6 (es) Un metodo para preparar derivados de piridil-y pirimidil-piperazinas.
IL86077A0 (en) Receptor of the small rhinovirus receptor group,its preparation and pharmaceutical compositions containing it
FI932490A0 (fi) Underenhetsvaccin mot Neisseria meningitidis-infektioner och motsvarande underenheter i rent tillstaond
GB9507883D0 (en) Compounds
GB9015774D0 (en) Novel treatment
IL104817A0 (en) Sugar derivatives of macrolides
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
ZA9427B (en) Use of riluzole for promoting restoration following radiation
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
RH1 Patent not in force